S&P Futures
4,164.50+4.50(+0.11%)Dow Futures
34,163.00+45.00(+0.13%)Nasdaq Futures
13,512.75+21.75(+0.16%)
iShares MSCI India ETF (INDA)
41.65 -0.03 (-0.07%)
After hours: 7:30PM EDT
| Previous Close | 40.97 |
| Open | 41.62 |
| Bid | 41.67 x 3000 |
| Ask | 41.65 x 4000 |
| Day's Range | 41.55 - 41.74 |
| 52 Week Range | 25.47 - 43.84 |
| Volume | 3,786,637 |
| Avg. Volume | 4,336,826 |
| Net Assets | 5.11B |
| NAV | 41.09 |
| PE Ratio (TTM) | N/A |
| Yield | 0.26% |
| YTD Daily Total Return | 3.95% |
| Beta (5Y Monthly) | 0.98 |
| Expense Ratio (net) | 0.69% |
| Inception Date | 2012-02-02 |
- GlobeNewswire
Revolution Medicines to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will deliver a corporate presentation at the Oppenheimer 31st Annual Healthcare Conference and be the featured speaker in a fireside chat at the J.P. Morgan 10th Annual Napa Valley Forum. Details of these events are as follows: Oppenheimer 31st Annual Healthcare ConferenceConference Date: March 16-18, 2021Presentation Time/Date: 1:10 – 1:40 p.m. Eastern on Tuesday, March 16, 2021Format: Virtual conference J.P. Morgan 10th Annual Napa Valley ForumConference Date: March 29-31, 2021Fireside Chat Time/Date: 2:00 – 2:45 p.m. Eastern on Monday, March 29, 2021Format: Virtual conference About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845. CONTACT: Contacts: For Investors: Vida Strategic Partners Stephanie Diaz 415-675-7401 sdiaz@vidasp.com For Media: Vida Strategic Partners Tim Brons 415-675-7402 tbrons@vidasp.com
- ETF.com
ETF Opens India Financials Door
Emerging markets are heating up, and India could be poised for massive growth.
